New Medical Center Ad Focuses on Groundbreaking Discoveries and Innovations
The University of Maryland Medical Center is home to many nationally and internationally recognized physicians and scientists who are faculty at the University of Maryland School of Medicine and perform pioneering research, and use the latest state-of-the-art technologies to advance the field of medicine and save lives. We bring together laboratory scientists and clinical investigators to better understand disease, develop new methods of treatment, and translate research results into clinical practice. At the University of Maryland Medical Center, ground-breaking discoveries are happening every day.
Watch the ads that highlight our Medical Center innovations above, and the University of Maryland Children's Hospital, here.
Aromatase inhibitors stop the production of estrogen that fuels the growth of cancer cells, and are widely used to treat postmenopausal women with hormone-responsive breast cancer. University of Maryland Marlene and Stewart Greenebaum Cancer Center research scientist, Dr. Angela Brodie, pioneered the development of this new class of drugs, which have also shown promise in preventing breast cancer in high-risk patients. Click here for more information
As part of a new personalized medicine initiative, the Medical Center offers genetic testing to help doctors determine which medication a patient should take after a stenting procedure in order to prevent blood clots that could lead to serious - and potentially fatal - heart attacks and strokes.
Fighting infectious disease is a key area for basic science research. Stefanie Vogel, PhD, professor in the departments of Microbiology and Immunology Medicine, is part of a team that found an experimental drug can treat influenza and prevent virus-induced lung injury and death, even when administered days after initial infection.
The University of Maryland Lung Transplant Team is the first in the country to use ex vivo lung perfusion to repair donor lungs prior to transplantation. This out-of-the-body technique in which donor lungs are evaluated and repaired, increases the donor lung pool significantly and provides more transplantable lungs to more than 1,700 on the waiting list. Click here for more information on the Lung Perfusion Program.
Cardiac surgeons at the University of Maryland Heart Center have implanted a ventricular assist device using a minimally invasive technique that employs small openings in the chest, a patient-friendly approach that provides the same results as traditional chest-splitting, open-heart surgery for heart pump implantation. For the patient, the new technique means quicker recovery, reduced chance of infection and minimal blood loss. Click here for more information about this procedure.
There are many factors that determine a patient’s wait time for an organ transplant, including severity of organ failure, blood type and overall health status. Studies have shown that patients who join wait lists at more than one transplant center have an increased chance of getting transplanted sooner. Double listing means that a patient has been evaluated and approved for the transplant wait list at two or more centers. As one of the busiest transplant program in the country, with wait times shorter than the national average for kidney and liver transplants, the University of Maryland Medical Center encourages patients to list with us as well as list with a transplant center close to home. Click here to learn more about double listing.
If you were diagnosed with heart failure 20 years ago, your chances of recovery were very low. Now, advances in medical and surgical treatments make it possible to slow, stop or reverse heart failure. And for patients in the advanced stages of heart failure, and are not eligible for a heart transplant, there are new ways to use ventricular assist devices – also called VADs – as a proven treatment option. Click here to learn more about the University of Maryland Medical Center’s Mechanical Heart and Lung Support Program.